Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BCYC logo BCYC
Upturn stock ratingUpturn stock rating
BCYC logo

Bicycle Therapeutics Ltd (BCYC)

Upturn stock ratingUpturn stock rating
$8.04
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/16/2025: BCYC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

13 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $26.27

1 Year Target Price $26.27

Analysts Price Target For last 52 week
$26.27Target price
Low$6.1
Current$8.04
high$28.67

Analysis of Past Performance

Type Stock
Historic Profit -15.84%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/16/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 502.12M USD
Price to earnings Ratio -
1Y Target Price 26.27
Price to earnings Ratio -
1Y Target Price 26.27
Volume (30-day avg) 13
Beta 1.47
52 Weeks Range 6.10 - 28.67
Updated Date 07/1/2025
52 Weeks Range 6.10 - 28.67
Updated Date 07/1/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.03

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -703.66%

Management Effectiveness

Return on Assets (TTM) -21.69%
Return on Equity (TTM) -37.07%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -304025629
Price to Sales(TTM) 19.52
Enterprise Value -304025629
Price to Sales(TTM) 19.52
Enterprise Value to Revenue 21.22
Enterprise Value to EBITDA -2.14
Shares Outstanding 47761800
Shares Floating 1884365
Shares Outstanding 47761800
Shares Floating 1884365
Percent Insiders 1.46
Percent Institutions 93.44

Analyst Ratings

Rating 4
Target Price 26.27
Buy 5
Strong Buy 5
Buy 5
Strong Buy 5
Hold 3
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Bicycle Therapeutics Ltd

stock logo

Company Overview

overview logo History and Background

Bicycle Therapeutics Ltd. was founded in 2009 and is headquartered in Cambridge, UK. The company is a biopharmaceutical company pioneering a new class of medicines based on its proprietary bicyclic peptide (Bicycleu00ae) technology.

business area logo Core Business Areas

  • Oncology: Developing Bicycle Toxin Conjugates (BTCs) and Bicycle Radio Conjugates (BRCs) for the treatment of cancer.
  • Other Therapeutic Areas: Exploring the potential of Bicycle technology in other therapeutic areas, including immune-oncology.

leadership logo Leadership and Structure

Dr. Kevin Lee is the Chief Executive Officer. The company has a Board of Directors composed of experienced individuals from the biotechnology and pharmaceutical industries. The organizational structure is typical of a biotechnology company, with research, development, clinical, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • BT8009: A Bicycle Toxin Conjugate (BTC) targeting Nectin-4, currently in Phase I/II clinical trials for advanced solid tumors. Market share data is not yet available as it is still in development. Competitors include companies developing antibody-drug conjugates (ADCs) targeting Nectin-4, such as Astellas/Seagen with PADCEV.
  • BT5500: A Bicycle Toxin Conjugate (BTC) targeting EphA2, currently in Phase I/II clinical trials for advanced solid tumors. Market share data is not yet available as it is still in development. Competitors include companies developing other EphA2 targeting therapies, such as ADCs or small molecule inhibitors.

Market Dynamics

industry overview logo Industry Overview

The biotechnology industry is highly competitive, with numerous companies developing novel therapeutics for various diseases. There is a growing focus on targeted therapies and personalized medicine.

Positioning

Bicycle Therapeutics is positioned as a pioneer in bicyclic peptide technology, offering a unique approach to drug development with potential advantages in terms of target specificity, tumor penetration, and safety.

Total Addressable Market (TAM)

The TAM for cancer therapeutics is estimated to be hundreds of billions of dollars annually. Bicycle Therapeutics is targeting specific cancer subtypes, which represent a significant portion of this overall market. The company's future is dependent on the success of its novel drug candidates.

Upturn SWOT Analysis

Strengths

  • Proprietary Bicycle technology platform
  • Potential for improved target specificity and tumor penetration
  • Strong intellectual property position
  • Experienced management team
  • Promising early-stage clinical data

Weaknesses

  • Early-stage clinical development
  • High risk of clinical trial failure
  • Dependence on partnerships for funding and commercialization
  • Limited commercial infrastructure

Opportunities

  • Expansion of Bicycle technology platform to new therapeutic areas
  • Potential for strategic partnerships and collaborations
  • Advancement of clinical programs to later stages
  • Potential for breakthrough therapy designations
  • Expansion of manufacturing capabilities

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Clinical trial failures
  • Patent challenges
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

  • MRNA
  • LLY
  • AZN

Competitive Landscape

Bicycle Therapeutics' competitive advantages lie in its proprietary Bicycle technology. Disadvantages include its relatively small size and limited resources compared to larger pharmaceutical companies. This data can change at any given moment.

Growth Trajectory and Initiatives

Historical Growth: Bicycle Therapeutics' historical growth is characterized by its advancement of its Bicycle platform and clinical programs.

Future Projections: Future projections for Bicycle Therapeutics are dependent on the success of its clinical trials and partnerships. Analyst estimates vary, but generally project significant growth potential if clinical milestones are achieved.

Recent Initiatives: Recent initiatives include advancing clinical trials for BT8009 and BT5500, expanding manufacturing capabilities, and exploring new partnerships.

Summary

Bicycle Therapeutics is a biotechnology company developing novel therapeutics based on its Bicycle platform. The company has promising early-stage clinical data and a strong intellectual property position. However, it faces the high risk of clinical trial failure and competition from larger pharmaceutical companies. Success depends on clinical milestones and partnerships.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Bicycle Therapeutics Ltd. website
  • SEC filings
  • Analyst reports
  • Industry news sources

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bicycle Therapeutics Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2019-05-23
CEO & Executive Director Dr. Kevin Lee M.B.A., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 305
Full time employees 305

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.